Metformina + Linagliptina Mylan (Metformin Hydrochloride, Linagliptin)

Metformina + Linagliptina is indicated for type 2 diabetes mellitus, targeting hyperglycemia through combined biguanide and DPP‑4 inhibition.

• Type 2 diabetes mellitus (monotherapy): improves fasting and post‑prandial glucose levels.
• Type 2 diabetes mellitus (combined therapy): enhances glycemic control when added to other antidiabetic agents.
• Type 2 diabetes mellitus (adjunct to diet and exercise): supports lifestyle measures to achieve target HbA1c.

• Metformin lowers hepatic gluconeogenesis and increases peripheral insulin sensitivity, while linagliptin binds to the active site of dipeptidyl peptidase‑4, preventing degradation of incretin hormones GLP‑1 and GIP. The preserved incretins stimulate glucose‑dependent insulin release and suppress glucagon secretion, together producing additive reductions in blood glucose. This dual action results in improved overall glycemic control without causing hypoglycemia when used alone.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset often occurring early in therapy.
• Diarrhea: loose stools that may resolve with continued use.
• Abdominal discomfort: cramping or pain in the stomach area.
• Headache: transient head pain without other neurological signs.
• Metallic taste: altered taste perception in the mouth.
• Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects

• Lactic acidosis: a life‑threatening buildup of lactate, especially in renal impairment.
• Severe hypoglycemia: marked low blood glucose, usually when combined with insulin or sulfonylureas.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• Acute renal failure: sudden loss of kidney function.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Anaphylactic reaction: severe allergic response with rash, swelling, or breathing difficulty.

Before initiating therapy, several safety considerations should be reviewed.

• Renal function assessment: evaluate creatinine clearance to avoid accumulation.
• Hepatic disease monitoring: use cautiously in patients with liver impairment.
• Risk of lactic acidosis: contraindicated in severe renal or hepatic failure.
• Pregnancy and lactation: safety not established; weigh benefits against risks.
• Elderly patients: start at lower dose and monitor for renal function.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Metformina + Linagliptina may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: can precipitate acute renal failure when combined with metformin.
• Concurrent use of other DPP‑4 inhibitors: may increase risk of adverse effects without added benefit.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics (thiazides): may enhance metformin‑related hypoglycemia.
• Corticosteroids: can increase blood glucose, requiring dose adjustments.
• Beta‑blockers: may mask hypoglycemia symptoms.
• Cimetidine: may reduce renal clearance of metformin.